MentalHealthDaily

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Vortioxetine Efficacy for Major Depression & Comorbid Anxiety (2023 Study)

by GLOOM

The RELIEVE study provides pivotal insights into the effectiveness of vortioxetine in treating patients with Major Depressive Disorder (MDD) co-morbid with Generalized Anxiety Disorder (GAD). A subgroup analysis of the observational study highlights significant improvements in patient functioning, depression severity, cognitive symptoms, and quality of life. The findings underscore vortioxetine’s potential as a beneficial treatment …

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

by GLOOM

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …

Polyphenols & Depression: Antidepressant Potential of Plant Compounds

by GLOOM

Depression, a prevalent and debilitating mental health condition, affects millions worldwide. Recent studies have shown an intriguing link between dietary polyphenols, naturally occurring compounds in plant-based foods, and depression outcomes. Highlights: Prevalence of Depression: More than 300 million people globally suffer from depression, marking it as a leading cause of disability. Role of Polyphenols: Polyphenols, …

Mitophagy & Depression: Mitochondrial Autophagy as an Antidepressant Target?

by GLOOM

Depression is a pervasive mental health issue with complex origins and often inadequate treatment options. Recent studies have suggested that mitophagy, the process of selective mitochondrial autophagy, plays a crucial role in the onset and progression of depression, offering new insights into its pathogenesis and potential treatments. Highlights: Major Depressive Disorder (MDD) affects millions globally, …

Trends in U.S. Medicaid Antidepressant Prescriptions: Newer Drugs & Higher Costs (2023 Analysis)

by GLOOM

The U.S. Medicaid program’s spending and prescribing patterns for antidepressants between 2017 and 2021 reveal a significant shift toward newer and costlier medications. Highlights: Rising Expenditure: Medicaid’s spending on antidepressants increased from approximately $1 billion in 2017 to $1.12 billion in 2021. Preference Shift: There’s been a significant shift from older antidepressants like TCAs and …